Simon Quick Advisors LLC Purchases New Position in Insulet Corporation $PODD

Simon Quick Advisors LLC purchased a new stake in Insulet Corporation (NASDAQ:PODD) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 1,224 shares of the medical instruments supplier’s stock, valued at approximately $385,000.

A number of other hedge funds also recently bought and sold shares of PODD. American Century Companies Inc. lifted its holdings in Insulet by 34.8% during the first quarter. American Century Companies Inc. now owns 1,152,606 shares of the medical instruments supplier’s stock worth $302,686,000 after buying an additional 297,734 shares during the period. Nuveen LLC purchased a new stake in Insulet during the first quarter worth $74,163,000. Kayne Anderson Rudnick Investment Management LLC lifted its holdings in Insulet by 1,316.5% during the first quarter. Kayne Anderson Rudnick Investment Management LLC now owns 193,511 shares of the medical instruments supplier’s stock worth $50,818,000 after buying an additional 179,850 shares during the period. Vanguard Group Inc. lifted its holdings in Insulet by 2.1% during the first quarter. Vanguard Group Inc. now owns 8,668,952 shares of the medical instruments supplier’s stock worth $2,276,553,000 after buying an additional 178,976 shares during the period. Finally, AustralianSuper Pty Ltd lifted its holdings in Insulet by 487.5% during the second quarter. AustralianSuper Pty Ltd now owns 205,168 shares of the medical instruments supplier’s stock worth $64,460,000 after buying an additional 170,247 shares during the period.

Insider Buying and Selling

In other news, SVP Prem Singh sold 687 shares of the firm’s stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $347.49, for a total transaction of $238,725.63. Following the completion of the sale, the senior vice president owned 3,456 shares in the company, valued at $1,200,925.44. This trade represents a 16.58% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Laetitia Cousin sold 797 shares of the firm’s stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $348.81, for a total transaction of $278,001.57. Following the sale, the senior vice president owned 3,890 shares of the company’s stock, valued at $1,356,870.90. This represents a 17.00% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.39% of the stock is owned by company insiders.

Insulet Trading Up 0.3%

PODD opened at $313.01 on Monday. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.26 and a quick ratio of 1.81. The company’s 50 day simple moving average is $326.58 and its two-hundred day simple moving average is $307.67. Insulet Corporation has a 1-year low of $227.03 and a 1-year high of $353.50. The firm has a market capitalization of $22.03 billion, a price-to-earnings ratio of 95.14, a price-to-earnings-growth ratio of 2.64 and a beta of 1.40.

Insulet (NASDAQ:PODD) last released its earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share for the quarter, topping analysts’ consensus estimates of $0.92 by $0.25. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The business had revenue of $649.10 million for the quarter, compared to analyst estimates of $612.31 million. During the same period last year, the company posted $0.55 EPS. The business’s revenue was up 32.9% on a year-over-year basis. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Analysts expect that Insulet Corporation will post 3.92 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently commented on PODD shares. The Goldman Sachs Group decreased their price objective on Insulet from $399.00 to $375.00 and set a “buy” rating for the company in a report on Wednesday, October 1st. Citigroup reissued a “buy” rating on shares of Insulet in a research report on Tuesday, July 8th. Oppenheimer increased their price target on Insulet from $324.00 to $365.00 and gave the stock an “outperform” rating in a research report on Monday, September 8th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Insulet in a research report on Thursday, August 7th. Finally, Morgan Stanley restated an “overweight” rating on shares of Insulet in a research report on Thursday, August 7th. One analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $352.11.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.